Contact Us
  • Home
  • About
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Research
  • The Technology
    • Cole Relaxation Frequency
    • Platform Technology
    • Predictive Technology
    • MarginScan™
    • BiopsyScan™
    • Targeted Drug Delivery
    • FastScan™ Probe
    • Electrical Mammogram
  • Clinical Results
  • Press
  • Contact Us
  • Home
  • About
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Research
  • The Technology
    • Cole Relaxation Frequency
    • Platform Technology
    • Predictive Technology
    • MarginScan™
    • BiopsyScan™
    • Targeted Drug Delivery
    • FastScan™ Probe
    • Electrical Mammogram
  • Clinical Results
  • Press
  • Contact Us
  • Home
  • About
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Research
  • The Technology
    • Cole Relaxation Frequency
    • Platform Technology
    • Predictive Technology
    • MarginScan™
    • BiopsyScan™
    • Targeted Drug Delivery
    • FastScan™ Probe
    • Electrical Mammogram
  • Clinical Results
  • Press
  • Contact Us

About

Recent Posts

  • NovaScan Announces Launch of its nsCanary™ Lung Trial at University of Chicago
  • PHC Corporation and NovaScan, Inc. Launch Collaboration to Explore the Feasibility of a Device that Supports Non-melanoma Skin Cancer Detection
  • NovaScan’s nsCanary™ Tech Platform Named One of Five Finalists in AGA’s Shark Tank Competition
  • NovaScan Announces the Launch of a Human GI trial for its nsCanary™ Cancer Detection Device
  • NovaScan Invited for Poster Presentation at ACG Annual Meeting

Recent Comments

No comments to show.

Easy to use, ex vivo and in vivo cancer detection that provides instantaneous, highly accurate results, without capital equipment.

 

Address

NovaScan, Inc.
965 W Chicago Ave
Chicago, IL 60642

Contact

Email: cdavis@novascanllc.com
Phone: 312-952-7701

© 2023 NovaScan LLC. All Rights Reserved